

# Thoughtful Brands Inc.

09:05 02 Jun 2020

## Mota Ventures closes acquisition of European psychedelics company Verrian Ontario

Mota Ventures Corp (CSE:MOTA) (OTCPINK:PEMTF) has completed its C\$20 million acquisition of European psychedelic medicine company Verrian Ontario Ltd by acquiring all the firm's outstanding share capital.

Verrian specializes in products related to addiction reduction, with a particular focus on alcohol and opiates. The company operates a 110,000 square-foot pharmaceutical manufacturing facility in Radebuel, Germany.

Verrians's manufacturing site includes an analytical laboratory and finished-dose manufacturing. Its facilities and equipment have been independently appraised at C\$10.6 million.

### READ: Mota Ventures to acquire natural wellness ecommerce platform Unified Funding

Mota has issued 54.3 million common shares to existing Verrian shareholders at a price of C\$0.37 per share. The move propels Mota into a psychedelic market worth up to US\$ 100 billion by some estimates.

The massive shift towards psychedelic-derived medicines is no longer in doubt and this acquisition sends a strong signal to the market that Mota Ventures intends to be a serious participant this coming decade," Mota CEO Ryan Hoggan said in a statement.

"Unlike some companies that use psychedelics as a marketing term, this acquisition of Verrian brings Mota market-ready products, world-renowned addiction medicine experts, R&D facilities and a 110,000 square foot facility to make it happen. In my opinion, this is the most complete psychedelic asset on the market, and therefore should immediately make Mota a market leader in the space."

Verrian's focus is rewiring the mind to overcome addiction, the company said. Specifically, micro-dosing psilocybin has shown the potential to remove the dopamine reward of addictive substances, potentially reducing the desire to use them.

The company has developed a pair of psilocybin products, PSI GEN and PSI GEN+, which are designed to reduce opiate addiction.


In addition to its facilities, Verrian has invested C\$2.4 million into clinical trial design and the development of a proprietary formulation for its PSI-GEN products, as well as its cannabis products, CBDaily and CBNight.

"In 2020, we have proven our e-commerce ability to acquire tens of thousands of customers and generate millions of dollars in monthly revenues from CBD sales," Hoggan said. "We intend to bring that same market expertise to bear with our psychedelics business in 2020 and far beyond."

**Price:** 0.055

**Market Cap:** \$13.57 m

### 1 Year Share Price Graph



January 2020 July 2020 January 2021

### Share Information

**Code:** TBI

**Listing:** CSE

<b>52 week</b>	<b>High</b>	<b>Low</b>
	<b>0.295</b>	<b>0.05</b>

**Sector:** Cannabis

**Website:** thoughtful-brands.com

### Company Synopsis:

Thoughtful Brands Inc. is an eCommerce technology company that develops, produces and markets natural health products through various brands in North America and Europe utilizing its proprietary direct-to-consumer platform. Through continuous strategic acquisitions, the company has a strong footprint in the CBD and nutraceutical product markets.

[action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

Contact Andrew Kessel at [andrew.kessel@proactiveinvestors.com](mailto:andrew.kessel@proactiveinvestors.com)

Follow him on Twitter [@andrew\\_kessel](https://twitter.com/andrew_kessel)

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 [action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

### No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Thoughtful Brands Inc. named herein, including the promotion by the Company of Thoughtful Brands Inc. in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).